Group items tagged

Participatory medicine will owe part of its success to the technologies that have the potential to remove treatment, symptom management, administrative, and communications burdens from individuals and clinicians while maintaining the critical interpersonal interactions between them. Out of the steady stream of new devices, programs, gadgets, and applications, which will make a difference in the health and lives of patients? We hope to build the Journal as a resource for critical reviews of technologies that support and facilitate participatory medicine. We realize it will be no small undertaking to put together a process that will allow for the review of a substantial number of technologies over time, reflecting the experience of different types of users.

Skinner JS, Staiger DO, Fisher ES. Is technological change in medicine always worth it? The case of acute myocardial infarction. Health Aff (Millwood) 2006;25:w34-w47.

It was concluded that omega-3 fatty acid could inhibit the proliferation of pancreatic cancer cell line SW1990 cells and promote their apoptosis. The down-regulation of the cyclin E expression by omega-3 fatty acid might be one of the mechanisms for its anti-tumor effect on pancreatic cancer. \n\nModulatory effects of EPA and DHA on proliferation and apoptosis of pancreatic cancer cells.\nZhang W, Long Y, Zhang J, Wang C.\nJ Huazhong Univ Sci Technolog Med Sci. 2007 Oct;27(5):547-50.\nPMID: 18060632

"More than three-quarters of healthcare executives believe their industry's most valuable asset is going to be information contained in electronic medical records...hundreds of billions of gigabytes of health and medical information will be industry's most valuable asset in 5 years. The value, however, must be unlocked by finding ways to overcome a lack of standards, privacy concerns, and technology limitations that could hinder use of the data." || NOTE: This data has already been used by private medical insurance companies to dig up "preexisting conditions" that allow them to drop coverage (rescission) on potentially unprofitable subscribers. ||

Abbott Announces Positive Six-Month Results from the World's First Clinical Trial of A Fully Bioabsorbable Drug-Eluting Coronary Stent\nAbbott's Bioabsorbable Stent Technology Holds Promise as Future-Generation Treatment Option for Physicians Treating Pati

Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents (Randomized TRIAS HR Pilot Study)